CR20220153A - Derivados de 2–azaespiro [3.4] octano como agonistas de m4 - Google Patents

Derivados de 2–azaespiro [3.4] octano como agonistas de m4

Info

Publication number
CR20220153A
CR20220153A CR20220153A CR20220153A CR20220153A CR 20220153 A CR20220153 A CR 20220153A CR 20220153 A CR20220153 A CR 20220153A CR 20220153 A CR20220153 A CR 20220153A CR 20220153 A CR20220153 A CR 20220153A
Authority
CR
Costa Rica
Prior art keywords
agonists
azaspiro
oxa
octane derivatives
octane
Prior art date
Application number
CR20220153A
Other languages
English (en)
Inventor
Amy Calhoun
Keith Jendza
Nancy Labbe-Giguere
Christopher G Thomson
Edward Charles Hall
James Neef
Daniel Steven Palacios
Ming Qian
Xin Chen
Kevin Matthew Gardinier
Michael David Shultz
Kate Yaping Wang
Fan Yang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20220153A publication Critical patent/CR20220153A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Abstract

En el presente documento se proporcionan compuestos de acuerdo con la Fórmula (I) o su sal farmacéuticamente aceptable, en donde R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup>, y R<sup>7</sup> se definen en el presente documento. También se proporcionan en el presente documento composiciones farmacéuticas que comprenden un compuesto de Fórmula (I) así como el uso de dichos compuestos como agonistas del receptor M4.
CR20220153A 2019-10-09 2020-10-07 Derivados de 2–azaespiro [3.4] octano como agonistas de m4 CR20220153A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962912986P 2019-10-09 2019-10-09
PCT/IB2020/059431 WO2021070091A1 (en) 2019-10-09 2020-10-07 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists

Publications (1)

Publication Number Publication Date
CR20220153A true CR20220153A (es) 2022-05-03

Family

ID=72944206

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220153A CR20220153A (es) 2019-10-09 2020-10-07 Derivados de 2–azaespiro [3.4] octano como agonistas de m4

Country Status (20)

Country Link
US (2) US11485742B2 (es)
EP (1) EP4041737A1 (es)
JP (1) JP7349567B2 (es)
KR (1) KR20220079608A (es)
CN (1) CN114555606A (es)
AR (1) AR120169A1 (es)
AU (1) AU2020364186B2 (es)
CA (1) CA3155589A1 (es)
CL (1) CL2022000892A1 (es)
CO (1) CO2022004391A2 (es)
CR (1) CR20220153A (es)
EC (1) ECSP22027784A (es)
IL (1) IL291600A (es)
JO (1) JOP20220084A1 (es)
MX (1) MX2022004215A (es)
PE (1) PE20221454A1 (es)
TW (1) TW202128703A (es)
UY (1) UY38907A (es)
WO (1) WO2021070091A1 (es)
ZA (1) ZA202202913B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221453A1 (es) * 2019-10-09 2022-09-21 Novartis Ag Derivados de 2-azaspiro[3,4]octano como agonistas de m4
WO2024059249A1 (en) * 2022-09-16 2024-03-21 Cerevel Therapeutics, Llc M4 activators/modulators and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276520A1 (en) 2002-11-13 2006-12-07 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
WO2006006490A1 (ja) 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
US7880007B2 (en) 2004-11-29 2011-02-01 Vertex Pharmaceuticals Incorporated Bicyclic substituted phenyl piperidine modulators of muscarinic receptors
JP5420408B2 (ja) 2006-08-25 2014-02-19 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１型のインヒビター
US20090291134A1 (en) * 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
AU2009309988A1 (en) 2008-10-29 2010-05-06 Grunenthal Gmbh Substituted spiroamines
CN102361876B (zh) 2009-01-26 2015-02-04 以色列生物研究所 二环杂环螺环化合物
CA2815120A1 (en) 2010-11-08 2012-05-18 Jose Ignacio Andres-Gil Radiolabelled mglur2 pet ligands
EP2675812B1 (en) 2011-02-18 2017-08-30 Vertex Pharmaceuticals Incorporated Chroman - spirocyclic piperidine amides as modulators of ion channels
JP6062432B2 (ja) 2011-07-27 2017-01-18 ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． プロテインキナーゼ阻害薬用スピロ環状分子
WO2014039489A1 (en) 2012-09-07 2014-03-13 Zoetis Llc Spirocyclic derivatives as antiparasitic agents
DK2897948T3 (en) 2012-09-18 2016-12-05 Heptares Therapeutics Ltd BICYCLIC AZA RELATIONS AS MUSCARIN M1 RECEPTOR AGONISTS
JP6479029B2 (ja) * 2014-02-06 2019-03-06 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
CN107108597B (zh) 2014-10-31 2020-04-17 英立维尔英国有限公司 多巴胺d3受体拮抗剂化合物
GB201504675D0 (en) 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513743D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB2540998A (en) 2015-08-04 2017-02-08 Phagenesis Ltd Catheter
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
BR122024002146A2 (pt) * 2016-06-10 2024-03-05 Vitae Pharmaceuticals, Inc. Compostos inibidores da interação de menina-llm e forma cristalina destes
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
EP4219464A1 (en) 2018-03-23 2023-08-02 Pfizer Inc. Piperazine azaspiro derivaves
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
PE20221454A1 (es) 2022-09-21
AU2020364186B2 (en) 2023-11-30
CO2022004391A2 (es) 2022-04-29
US20220411435A1 (en) 2022-12-29
US11485742B2 (en) 2022-11-01
CN114555606A (zh) 2022-05-27
ECSP22027784A (es) 2022-05-31
US11820778B2 (en) 2023-11-21
AR120169A1 (es) 2022-02-02
US20210130365A1 (en) 2021-05-06
JP7349567B2 (ja) 2023-09-22
WO2021070091A1 (en) 2021-04-15
ZA202202913B (en) 2023-06-28
JP2022551853A (ja) 2022-12-14
EP4041737A1 (en) 2022-08-17
CL2022000892A1 (es) 2023-01-20
MX2022004215A (es) 2022-05-03
JOP20220084A1 (ar) 2023-01-30
IL291600A (en) 2022-05-01
AU2020364186A1 (en) 2022-04-21
KR20220079608A (ko) 2022-06-13
UY38907A (es) 2021-05-31
CA3155589A1 (en) 2021-04-15
TW202128703A (zh) 2021-08-01

Similar Documents

Publication Publication Date Title
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
MA42339A1 (fr) Modulateurs du récepteur farnésoïde x
MX2021010314A (es) Derivados de tiazol como inhibidores de la secreción de proteínas.
CY1113395T1 (el) Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
ZA202201503B (en) Urea compound for antagonizing lpa1 receptor
MX2020002430A (es) Compuestos inhibidores del receptor 1 del acido lisofosfatidico (lpar1).
WO2020081410A3 (en) Radioligands for imaging the lpa1 receptor
CR20220153A (es) Derivados de 2–azaespiro [3.4] octano como agonistas de m4
CR20220141A (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
MX2021014680A (es) Derivado de benzotriazol.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
WO2021026479A9 (en) Small molecule inhibitors of s1p2 receptor and uses thereof
WO2020102053A8 (en) Methods of preparing cytotoxic benzodiazepine derivatives
CR20210173A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.
MX2022005415A (es) Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo.
PH12021550248A1 (en) Borate of azetidine derivative
MX2022002941A (es) Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo.
WO2020139971A3 (en) Methods for making dimeric naphthalimides and solid state forms of the same
MX2022006776A (es) Composiciones farmaceuticas oftalmicas.
BR112022006386A2 (pt) Derivados de 2-azaspiro[3.4]octano como agonistas de m4